Skip to content

Labcorp Holdings

US · LH #790 by market cap Listed 1970
367.13 -1.75 -0.47%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.4 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
100.60% -0.39pp
Institutions
1,312 -2
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund88.13%
Hedge Fund4.44%
Public Company3.57%
Government Pension Fund1.28%
Private Company1.25%
Sovereign Wealth Fund1.04%
Individual/Insider0.38%
Family Office/Trust0.35%
Insurance Company0.26%

Top holders as of 2026-09-30

BlackRock 8.05% · 6.54M sh
Vanguard Capital Management, LLC 7.10% · 5.77M sh
State Street Global Advisors 4.86% · 3.94M sh
Victory Capital Management Inc. 4.83% · 3.92M sh
Vanguard Portfolio Management, LLC 4.46% · 3.62M sh
FMR 4.24% · 3.45M sh
Boston Partners Global Investors, Inc. 3.63% · 2.95M sh
Geode Capital Management, LLC 2.69% · 2.19M sh
Allspring Global Investments, LLC 2.56% · 2.08M sh
Select Equity Group, L.P. 1.88% · 1.52M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 18 buys · 32 sells

NameRoleStake
Adam Schechter Chairperson & CEO 0.13%
Glenn Eisenberg Former Executive VP & Special Advisor to the CEO 0.05%
Brian Caveney Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer 0.04%
Lance Berberian Former Executive VP & Special Advisor - Strategy 0.02%
Peter Neupert Independent Director 0.02%
Garheng Albert Kong Vice Chairman & Lead Independent Director 0.02%
Mark Schroeder Former Executive VP, President of Diagnostics Laboratories & COO 0.02%
Kerrii Anderson Independent Director 0.01%
Amy Summy Executive VP, Chief Marketing Officer & Consumer Health Lead 0.01%
Bryan Vaughn Executive VP & President of Diagnostics 0.01%
D. Gilliland Former Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Brian Caveney Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer Open Market Disposition -2,000 $372.04
2026-11-03 Megan Bailey Former Executive VP and President of Central Laboratory Services & International Labcorp Intent to Sell (Form 144) -3,035 $361.16
2026-11-02 Bryan Vaughn Executive VP & President of Diagnostics Automatic Disposition -306 $353.70
2026-11-01 Akinbolade Oyegunwa Executive VP and Chief Information & Technology Officer Derivative Exercise and Sale -118 $355.59
2026-11-01 Bryan Vaughn Executive VP & President of Diagnostics Derivative Exercise and Sale -194 $355.59
2026-10-31 Akinbolade Oyegunwa Executive VP and Chief Information & Technology Officer Derivative Exercise and Retained +252 --
2026-10-31 Bryan Vaughn Executive VP & President of Diagnostics Derivative Exercise and Retained +306 --
2026-10-29 Richelle Parham Independent Director Open Market Disposition -1,078 $361.22
2026-08-31 Brian Caveney Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer Other Derivative Acquisition +3,000 --
2026-08-31 Akinbolade Oyegunwa Executive VP and Chief Information & Technology Officer Other Derivative Acquisition +750 --
2026-08-31 Jonathan Meltzer Chief Operating Officer Other Derivative Acquisition +900 --
2026-08-31 Bryan Vaughn Executive VP & President of Diagnostics Other Derivative Acquisition +1,500 --
2026-08-16 Kerrii Anderson Independent Director Automatic Disposition -3,000 $318.02
2026-08-10 Adam Schechter Chairperson & CEO Automatic Disposition -4,669 $320.37
2026-08-03 Amy Summy Executive VP, Chief Marketing Officer & Consumer Health Lead Open Market Disposition -924 $306.74
2026-08-02 Peter Wilkinson Chief Accounting Officer Open Market Disposition -82 $309.22
2026-08-02 Peter Wilkinson Chief Accounting Officer Derivative Exercise and Sale -1,338 $209.25–309.23
2026-07-01 Kathryn Kyle Executive Vice President Derivative Exercise and Sale -165 $283.88–286.19
2026-07-01 Kathryn Kyle Executive Vice President Intent to Sell (Form 144) -92 $286.19
2026-07-01 Bryan Vaughn Executive VP & President of Diagnostics Derivative Exercise and Sale -327 $283.88–286.19

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Labcorp Holdings discussion 0 comments

Add a comment